Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the safety and efficacy of oral RG2417
(Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.